SCM
BMRN icon

Silverarc Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Silverarc Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$885K – 74
2023
Q3 		$885K Hold
10,000
– – 0.27% 61
2023
Q2 		$867K Buy
+10,000
New +$941K 0.27% 61

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Silverarc Capital Management's BMRN Position: Q4 2023 in Review

Silverarc Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 10,000 shares — an estimated $885K sold.

Silverarc Capital Management first reported a position in BMRN in Q2 2023 and held it in 2 quarters. The position peaked at $885K in Q3 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Silverarc Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 10,000 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $885K.
  • Silverarc Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Silverarc Capital Management's BioMarin Pharmaceuticals position peaked at $885K in Q3 2023.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.